New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
08:33 EDTDXCM, ABTDexCom reports settlement and license agreement with Abbott Diabetes Care
On July 2, DexCom (DXCM) entered into a Settlement and License Agreement with Abbott Diabetes Care (ABT). The Settlement Agreement was entered into in full settlement of all pending patent infringement legal proceedings brought by Abbott against the Company. The Settlement Agreement obligates the parties to promptly file a joint stipulation of dismissal of all pending legal proceedings.The Settlement Agreement does not obligate the company to pay any royalties or any other form of financial compensation. The Settlement Agreement provides for a royalty-free, worldwide, non-exclusive, non-sublicensable cross-license of certain patents. The company receives a limited license from Abbott to the patents that Abbott has alleged that the company infringed. The company grants to Abbott a limited license of certain patents with an actual filing date prior to January 1, 2005. In addition, each party agrees not to (1) sue the other party for patent infringement based on certain of their respective continuous glucose monitoring products, and (2) challenge any patent or patent application held by the other party, subject to certain limited exceptions, in each case, until March 31, 2021. The cross-license and mutual covenant not to sue granted to each party do not apply to the type of sensor technology used by the other party. Comments taken from an 8-K filing.
News For DXCM;ABT From The Last 14 Days
Check below for free stories on DXCM;ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
08:15 EDTABTEnzo Biochem announces August 18 as date of Markman hearing in lawsuit
Subscribe for More Information
July 28, 2014
11:07 EDTABTLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
07:30 EDTABTQ1 Productions to hold a conference
Subscribe for More Information
07:26 EDTABTAmerican Association for Clinical Chemistry to hold annual meeting
Subscribe for More Information
06:52 EDTABTFormer official says Obama could limit inversion deals, NY Times reports
President Obama could limit tax inversion deals on his own authority, said Stephen Shay, former deputy assistant Treasury secretary for international tax affairs in the Obama administration, according to The New York Times. A 1969 law gives the president the ability to restrict inversion deals, said Shay, who also worked in the Reagan administration, the newspaper stated. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Alletgan (AGN). Reference Link
July 25, 2014
07:32 EDTABTAmerican Veterinary Medical Association to hold a conference
Subscribe for More Information
06:30 EDTABTObama calls on Congress to end inversion deals, NY Times reports
Subscribe for More Information
July 24, 2014
14:35 EDTABTObama to call for elimination of tax inversion deals, NY Times says
President Obama will call on Congress today to eliminate the tax inversion loophole, according to The New York Times. Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott’s (ABT), Medtronic's acquisition of Covidien (COV)and Valeant's (VRX) proposed takeover of Alletgan (AGN)Reference Link
July 23, 2014
10:27 EDTABTHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
06:45 EDTABTLawmakers divided on inversion deals, NY Times says
Subscribe for More Information
July 18, 2014
16:47 EDTABTMarket ends week higher as earnings, M&A offset geopolitical tensions
Subscribe for More Information
12:51 EDTABTKey GOP senator signals readiness for inversion deal, The Hill says
Subscribe for More Information
July 17, 2014
07:06 EDTABTAbbott price target raised to $47 from $42 at Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use